# A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa

> **NCT04019041** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 153 (actual)

## Conditions studied

- Hidradenitis Suppurativa
- Acne Inversa
- Suppurative Hidradenitis

## Interventions

- **DRUG:** bermekimab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04019041
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-16
- **Primary completion:** 2020-05-19
- **Final completion:** 2020-11-17
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04019041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04019041, "A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04019041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*